Charles M Conway

US Patent:

6566361, May 20, 2003

Filed:

May 17, 2001

Appl. No.:

09/860181

Inventors:

Francoise Camborde - Orsay, FR
Alix Cloarec - Triel sur Seine, FR
Charles Conway - Cheshire CT

Assignee:

Laboratories, UPSA
Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31497

US Classification:

51425214, 51425215, 51425216, 51425217, 51425218, 51425219, 514922

Abstract:

A method of treating pain with acetaminophen comprises the concurrent administration of an azapirone such as buspirone. This combination of agents surprisingly results in a strengthened analgesic response characterized by rapid onset, greater pain relief, and a longer duration of action.

US Patent:

6511982, Jan 28, 2003

Filed:

Jan 4, 2001

Appl. No.:

09/754766

Inventors:

Francoise Camborde - Orsay, FR
Alix Cloarec - Triel sur Seine, FR
Charles Conway - Cheshire CT

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31497

US Classification:

51425215, 514922

Abstract:

A method of treating pain with acetaminophen comprises the concurrent administration of buspirone. This combination of agents surprisingly results in a morphine-like analgesic response characterized by rapid onset, greater pain relief, and a longer duration of action.

US Patent:

6593331, Jul 15, 2003

Filed:

Apr 4, 2002

Appl. No.:

10/115785

Inventors:

Francoise Camborde - Orsay, FR
Alix Cloarec - Triel sur Seine, FR
Charles Conway - Cheshire CT

Assignee:

Laboratories UPSA
Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31495

US Classification:

51425218, 514629

Abstract:

A method of treating pain with acetaminophen comprises the concurrent administration of a hydroxyazapirone selected from 6-hydroxybuspirone or 3-hydroxygepirone. This combination of agents results in a more morphine-like analgesic response characterized by rapid onset and greater pain relief.

US Patent:

20040063735, Apr 1, 2004

Filed:

May 27, 2003

Appl. No.:

10/445523

Inventors:

Prasad Chaturvedula - Cheshire CT, US
Ling Chen - Middletown CT, US
Rita Civiello - Killingworth CT, US
Charles Conway - Cheshire CT, US
Andrew Degnan - New Haven CT, US
Gene Dubowchik - Middlefield CT, US
Xiaojun Han - Cheshire CT, US
George Karageorge - Portland CT, US
Guanglin Luo - Madison CT, US
John Macor - Guilford CT, US
Graham Poindexter - Old Saybrook CT, US
Shikha Vig - Durham CT, US

International Classification:

A61K031/517
C 07D 4 3/14

US Classification:

514/266220, 544/284000

Abstract:

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

US Patent:

20040204397, Oct 14, 2004

Filed:

Dec 5, 2003

Appl. No.:

10/729155

Inventors:

Prasad Chaturvedula - Cheshire CT, US
Ling Chen - Middletown CT, US
Rita Civiello - Killingworth CT, US
Charles Conway - Cheshire CT, US
Andrew Degnan - New Haven CT, US
Gene Dubowchik - Middlefield CT, US
Xiaojun Han - Cheshire CT, US
Xiang J. Jiang - Hamden CT, US
George Karageorge - Portland CT, US
Guanglin Luo - Madison CT, US
John Macor - Guilford CT, US
Graham Poindexter - Old Saybrook CT, US
George Tora - Meriden CT, US
Shikha Vig - Durham CT, US

International Classification:

A61K031/541
A61K031/5377
A61K031/53
A61K031/496
A61K031/454

US Classification:

514/210200, 514/227500, 514/235200, 514/252110, 514/254010, 514/253010, 514/255010, 514/326000, 514/252140, 514/254020, 514/254050, 514/241000

Abstract:

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

US Patent:

20070148093, Jun 28, 2007

Filed:

Dec 19, 2006

Appl. No.:

11/641974

Inventors:

Charles Conway - Cheshire CT, US

International Classification:

A61K 49/00

US Classification:

424009200, 800003000

Abstract:

The present invention relates to in vivo non-terminal method of identifying anti-migraine compounds.

US Patent:

20220401439, Dec 22, 2022

Filed:

Dec 17, 2020

Appl. No.:

17/769966

Inventors:

- New Haven CT, US
Charles M. CONWAY - Cheshire CT, US
Robert CROOP - Newton Square PA, US
Rajesh KUMAR - Skillman NJ, US

International Classification:

A61K 31/496
A61K 9/00
A61M 11/04
A61P 25/00

Abstract:

Provided is pharmaceutical composition for intranasal delivery, wherein the pharmaceutical composition includes a therapeutically active ingredient including a CGRP inhibitor. Also provided is a method for delivering a CGRP inhibitor to a subject, wherein the method includes intranasally administering to the subject a composition including a therapeutically active component including a CGRP inhibitor.

US Patent:

20220249468, Aug 11, 2022

Filed:

Apr 10, 2020

Appl. No.:

17/602915

Inventors:

- Carson City NV, US
- New Haven CT, US
Aurélia GALUS - Weyersheim, FR
Thomas POINTEAUX - Reichstett, FR
Julien MEISSONNIER - Souffelweyersheim, FR
Gene M. DUBOWCHIK - New Haven CT, US
Charles M. CONWAY - New Haven CT, US

Assignee:

R.P. Scherer Technologies, LLC - Carson City NV
Biohaven Pharmaceutical Holding Company Ltd. - New Haven CT

International Classification:

A61K 31/496
A61K 47/14
C07K 16/18
A61K 47/26

Abstract:

The present disclosure is directed to a pharmaceutical formulation intended for oral delivery of synthetic or natural poorly permeable calcitonin gene-related peptide (CGRP) inhibitors or salts/solvates thereof having a therapeutic activity. The pharmaceutical formulation can include a synthetic or natural poorly permeable CGRP inhibitors or salt or solvate thereof in an amount 0.01-10 wt. % of the total weight of the formulation; a lipophilic phase comprising triglycerides of fatty acids in an amount of 50-80 wt. % of the total weight of the formulation; and at least one lipophilic surfactant comprising partial esters of polyol and fatty acids in an amount of about 10-50 wt. % of the total weight of the formulation.